Published online before print November 18, 2002, doi: 10.1161/01.CIR.0000043029.52803.7B
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:2888.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular Cells
From the Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.
Correspondence to Uwe Schönbeck, Cardiovascular Medicine, Brigham and Women’s Hospital, 221 Longwood Ave, EBRC309, Boston, MA 02115. E-mail uschoenbeck{at}rics.bwh.harvard.edu
Background— Although CD40 signaling participates in atherosclerosis, links between lipid risk factors and this inflammatory pathway remain obscure. Cardiovascular risk reduction by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may involve actions beyond lipid lowering, including reduced inflammation. Therefore, this study analyzed whether oxidized low-density lipoprotein (oxLDL) induces CD40/CD40L expression on cells implicated in atherogenesis and whether statins affect their expression in vitro as well as the expression of soluble CD40L (sCD40L) in vivo.
Methods and Results— Treatment of human vascular endothelial and smooth muscle cells and mononuclear phagocytes with oxLDL augmented the basal expression of CD40 and CD40L mRNA and protein. In contrast, cerivastatin, atorvastatin, or simvastatin concentration-dependently diminished the constitutive as well as oxLDL- or cytokine-induced expression of the receptor/ligand dyad, an effect reversed by mevalonate. Patients treated with statins had diminished sCD40L plasma levels compared with untreated control patients (8.3±3.1 ng/mL [n=11] versus 13.1±2.5 ng/mL [n=16], P<0.05), supporting the clinical relevance of the in vitro observations. Platelet-enriched plasma of mice deficient in CD40L showed markedly delayed fibrin clot formation, suggesting a role for the ligand in blood coagulation and supporting the hypothesis that statin-mediated reduction in CD40/CD40L expression might limit thrombosis.
Conclusions— OxLDL may promote expression of CD40 and CD40L in human atheroma. Statins may limit the expression of the CD40 receptor/ligand dyad in two ways, directly as well as through diminished lipoprotein levels. Thus, reduced CD40 signaling may account for some of the statins’ antiinflammatory action.
Key Words: atherosclerosis • inflammation • statins
This article has been cited by other articles:
 |
|
 |
|
  A. Gottsater, D. Flondell-Site, T. Kolbel, and B. Lindblad Associations Between Statin Treatment and Markers of Inflammation, Vasoconstriction, and Coagulation in Patients With Abdominal Aortic Aneurysm Vascular and Endovascular Surgery, December 1, 2009; 42(6): 567 - 573. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Martino, P. Pignatelli, E. Martino, F. Morrone, R. Carnevale, S. Di Santo, B. Buchetti, L. Loffredo, and F. Violi Early Increase of Oxidative Stress and Soluble CD40L in Children With Hypercholesterolemia J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1974 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Yanbaeva, M. A. Dentener, E. C. Creutzberg, G. Wesseling, and E. F. M. Wouters Systemic Effects of Smoking Chest, May 1, 2007; 131(5): 1557 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Schrijvers, G. R.Y. De Meyer, A. G. Herman, and W. Martinet Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability Cardiovasc Res, February 1, 2007; 73(3): 470 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. D'Alimonte, V. Flati, M. D'Auro, E. Toniato, S. Martinotti, M. P. Rathbone, S. Jiang, P. Ballerini, P. Di Iorio, F. Caciagli, et al. Guanosine Inhibits CD40 Receptor Expression and Function Induced by Cytokines and beta Amyloid in Mouse Microglia Cells J. Immunol., January 15, 2007; 178(2): 720 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Barani, I. Mattiasson, B. Lindblad, and A. Gottsater Cardiac Function, Inflammatory Mediators and Mortality in Critical Limb Ischemia Angiology, August 1, 2006; 57(4): 437 - 444. [Abstract] [PDF]
|
|
|
|
|
|
K. Morimoto, W. J. Janssen, M. B. Fessler, K. A. McPhillips, V. M. Borges, R. P. Bowler, Y.-Q. Xiao, J. A. Kench, P. M. Henson, and R. W. Vandivier Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J. Immunol., June 15, 2006; 176(12): 7657 - 7665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Ray and C. P. Cannon The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1425 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. de Lemos, A. Zirlik, U. Schonbeck, N. Varo, S. A. Murphy, A. Khera, D. K. McGuire, G. Stanek, H. S. Lo, R. Nuzzo, et al. Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2192 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Bavendiek, A. Zirlik, S. LaClair, L. MacFarlane, P. Libby, and U. Schonbeck Atherogenesis in Mice Does Not Require CD40 Ligand From Bone Marrow-Derived Cells Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1244 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E C Jury and M R Ehrenstein Statins: immunomodulators for autoimmune rheumatic disease? Lupus, March 1, 2005; 14(3): 192 - 196. [Abstract] [PDF]
|
|
|
|
 |
|
 V. Sanguigni, P. Pignatelli, L. Lenti, D. Ferro, A. Bellia, R. Carnevale, M. Tesauro, R. Sorge, R. Lauro, and F. Violi Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients Circulation, February 1, 2005; 111(4): 412 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Krettek, G. K. Sukhova, U. Schonbeck, and P. Libby Enhanced Expression of CD44 Variants in Human Atheroma and Abdominal Aortic Aneurysm: Possible Role for a Feedback Loop in Endothelial Cells Am. J. Pathol., November 1, 2004; 165(5): 1571 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pignatelli, V. Sanguigni, L. Lenti, D. Ferro, A. Finocchi, P. Rossi, and F. Violi gp91phox-Dependent Expression of Platelet CD40 Ligand Circulation, September 7, 2004; 110(10): 1326 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vishnevetsky, V. A Kiyanista, and P. J Gandhi CD40 Ligand: A Novel Target in the Fight Against Cardiovascular Disease Ann. Pharmacother., September 1, 2004; 38(9): 1500 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, W. J. Sasiela, M. Szarek, P. Ganz, P. Libby, and for the Myocardial Ischemia Reduction with Aggress Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Circulation, July 27, 2004; 110(4): 386 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mach Statins as Immunomodulatory Agents Circulation, June 1, 2004; 109(21_suppl_1): II-15 - II-17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck and P. Libby Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shimada, K. Miyauchi, H. Daida, S. Kinlay, P. Libby, P. Ganz, For the MIRACL Study Investigators, G. G. Schwartz, A. G. Olsson, N. Rifai, et al. Early Intervention With Atorvastatin Modulates Th1/Th2 Imbalance in Patients With Acute Coronary Syndrome: From Bedside to Bench * Response Circulation, May 11, 2004; 109(18): e213 - e214. [Full Text] [PDF]
|
|
|
|
|
|
P. E. Szmitko, C.-H. Wang, R. D. Weisel, J. R. de Almeida, T. J. Anderson, and S. Verma New Markers of Inflammation and Endothelial Cell Activation: Part I Circulation, October 21, 2003; 108(16): 1917 - 1923. [Full Text] [PDF]
|
|
|
|
|
|
N. Varo, J. A. de Lemos, P. Libby, D. A. Morrow, S. A. Murphy, R. Nuzzo, C. M. Gibson, C. P. Cannon, E. Braunwald, and U. Schonbeck Soluble CD40L: Risk Prediction After Acute Coronary Syndromes Circulation, September 2, 2003; 108(9): 1049 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mulhaupt, C. M Matter, B. R Kwak, G. Pelli, N. R Veillard, F. Burger, P. Graber, T. F Luscher, and F. Mach Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells Cardiovasc Res, September 1, 2003; 59(3): 755 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bereczki, E. Nagy, A. Pal, M. T. Magyar, J. Balla, G. J. Blake, R. J. Ostfeld, E. K. Yucel, N. Varo, U. Schonbeck, et al. Should Soluble CD40 Ligand Be Measured From Serum or Plasma Samples? * Arterioscler. Thromb. Vasc. Biol., June 12, 2003; 23(6): 1129 - 1130. [Full Text] [PDF]
|
|
|
|
|
|
N. Varo, D. Vicent, P. Libby, R. Nuzzo, A. L. Calle-Pascual, M. R. Bernal, A. Fernandez-Cruz, A. Veves, P. Jarolim, J. J. Varo, et al. Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones Circulation, June 3, 2003; 107(21): 2664 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mach Toward a Role for Statins in Immunomodulation Mol. Interv., December 1, 2002; 2(8): 478 - 480. [Abstract] [Full Text]
|
|